Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
Jeff Jonas Remains As Chief Innovation Officer, Board Member
Executive Summary
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
You may also be interested in...
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
Alnylam CEO Maraganore To Step Aside At End Of 2021
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
J.P. Morgan 2021: The Show Must Go On
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.